Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2012

View Archived Issues

Phase I and II data presented for semaglutide

Zalypsis ineffective in urothelial carcinoma

Genentech begins phase II trials of ADCs based on Seattle Genetics technology

Preliminary results given for TH-302 with bevacizumab in glioblastoma

In vitro, in vivo and phase I data on DS-8587 presented

Synageva BioPharma patents novel polypeptides

City of Hope discloses new siRNA systems for HIV

Researchers at Takeda Pharmaceutical design novel PDE10A inhibitors

Significant reduction of HbA1c seen with VRS-859 in clinical trial

New GCS activators synthesized by Boehringer Ingelheim

New LTA mimetics divulged by scientists in Germany and The Netherlands

Zafgen presents novel MetAP 2 inhibitors for obesity

Novavax begins phase II RSV vaccine study in women of childbearing age

Enrollment continues in Can-Fite BioPharma's phase II/III psoriasis study

U.K. authorities clear phase I malaria vaccine trial with Isconova's adjuvant Matrix-M

Aeras and GSK enter agreement on tuberculosis vaccine development

Phase I ACP-501 study meets primary endpoint in stable atherosclerosis

New NICE guidance on Crohn's disease released

Crucell signs agreement to use Mucosis' platform for vaccine program

Researchers find possible biomarker for renal cell carcinoma

MedGenesis obtains new grant to develop glial cell line product

Oxford BioMedica provides update on TroVax development

Merck & Co. plans to initiate North American HDM AIT study

Canadian commercialization agreement set for MoxDuo

Cleveland BioLabs and Incuron announce start of phase I trial of CBLC-137

Navidea provides update on Lymphoseek NDA

FDA grants QIDP designation to radezolid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
mRNA flu vaccine can activate broad germinal center response
BioWorld
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...